-
公开(公告)号:CZ20010508A3
公开(公告)日:2001-07-11
申请号:CZ20010508
申请日:1999-07-20
Applicant: BASF AG
Inventor: STEINER GERD , HOGER THOMAS , UNGER LILIANE , TESCHENDORF HANS-JUGEN , JUCHELKA FRIEDER
IPC: A61K31/427 , A61P25/00 , C07D417/06
-
公开(公告)号:ID28787A
公开(公告)日:2001-07-05
申请号:ID20011198
申请日:1999-10-28
Applicant: BASF AG
Inventor: LUBISCH WILLFRIED , KOCK MICHAEL , HOGER THOMAS
IPC: G01N33/53 , A61K31/00 , A61K31/4184 , A61K31/4427 , A61K31/454 , A61K31/496 , A61K31/55 , A61P3/10 , A61P9/00 , A61P9/10 , A61P11/00 , A61P13/12 , A61P25/08 , A61P25/10 , A61P25/28 , A61P29/00 , A61P35/00 , A61P37/00 , A61P43/00 , C07C237/30 , C07D235/18 , C07D401/10 , C07D403/10 , C07D521/00 , C12Q1/48 , G01N33/00 , G01N33/15 , G01N33/573 , G01N33/577
Abstract: 2-Phenyl-benzimidazolecarboxamide derivatives (I) and (II) are new. 2-Phenyl-benzimidazolecarboxamide derivatives of formulae (I) and (II) and their tautomers, enantiomers, diastereomers, prodrugs and salts, are new: [Image] R 1>H or alkyl optionally substituted with OH, alkoxy, amino (optionally mono- or disubstituted) or optionally substituted piperidino, piperazino, pyrrolidino, hexahydroazepino, morpholino or 4,5-dihydropyridino; R 2>H, Cl, Br, I, F, CF 3, NO 2, NHCOR 2> 1>, NR 2> 2>R 2> 3>, OH, alkoxy, alkoxy-Ph, NH 2, or Ph; R 2> 1>, R 2> 2>alkyl; R 2> 3>H, alkyl, or optionally substituted phenyl; x : 0-2; R 3>D-(F 1>) p-(E) q-(F 2>) r-G, E-(D) u-(F 2>) s-(G) v or B; R 4>H, Cl, F, Br, I, alkyl, OH, NO 2, CF 3, CN, NR 4> 4>R 4> 2>, NHCOR 4> 3>, or alkoxy; R 4> 1>, R 4> 2>H or alkyl; R 4> 3>H, alkyl, alkyl-phenyl, or phenyl; D : O or S; E : phenyl, imidazole, pyrrole, thiophene, pyridine, pyrimidine, piperazine, pyrazine, furan, thiazole, isoxazole, pyrrolidine, piperidine or optionally substituted trihydroazepine ring; F 1>, F 2>1-8C chain optionally substituted with OH or alkoxy; p-v : 0 or 1, but p, q and r are not simultaneously 0; G : NR 5> 1>R 52>or optionally substituted pyrrolidinyl, piperidinyl, 1,2,5,6-tetrahydropyridyl, piperizinyl, azepinyl, morpholinyl or 1,4-diazepanyl; R 5> 1>alkyl or (CH 2) t-K; B : optionally substituted pyrrolidinyl, piperidinyl, 1,2,5,6-tetrahydropyridyl, piperizinyl, azepinyl, morpholinyl or 1,4-diazepanyl; t : 0-4; K : optionally substituted phenyl, NR 4> 1>R 4> 2>, phenyl-alkyl-NH, pyrrolidino, piperidino, 1,2,5,6-tetrahydropyridino, morpholino, trihydroazepino, or piperazino or homopiperazino (both optionally substituted with alkyl); R 5>H, alkyl, NR 7>R 9>, or optionally substituted pyrrolidinyl, piperidinyl, 1,2,5,6-tetrahydropyridyl, piperizinyl, azepinyl, morpholinyl or 1,4-diazepanyl; The full definitions are given in the DEFINITIONS (Full Definitions) Field. Independent claims are also included for the following: (i) aminobenzamide intermediates of formulae (III) and (IV) and their salts; (ii) preparation of compounds (III) and (IV); (iii) an in vitro method for the detection of poly(ADP-ribose)polymerase (PARP) inhibitors comprising: (a) incubating a poly-ADP-ribosylable target (optionally bonded to a carrier) with a reaction mixture comprising a PARP, a PARP activator and a PARP inhibitor or an analyte in which one or more PARP inhibitors is presumed to exist; (b) carrying out a poly-ADP-ribosylation reaction; and (c) qualitatively or quantitatively determining the poly-ADP-ribosylation with an anti-poly-(ADP-ribose) antibody. [Image] ACTIVITY : None given. MECHANISM OF ACTION : Poly(ADP-ribose)polymerase (PARP) inhibitor.
-
93.
公开(公告)号:NZ502675A
公开(公告)日:2001-06-29
申请号:NZ50267598
申请日:1998-08-14
Applicant: BASF AG
Inventor: HOGER THOMAS , BLANK STEFAN , STARCK DOROTHEA , TREIBER HANS-JORG , KOSER STEFAN , SCHAFER BERND , THYES MARCO
IPC: A61K20060101 , A61K31/395 , C07D239/56 , A61K31/497 , A61K31/505 , A61K31/506 , A61P1/08 , A61P25/16 , A61P25/18 , A61P25/20 , A61P25/24 , A61P43/00 , C07D20060101 , C07D239/42 , C07D239/46 , C07D295/125 , C07D403/00 , C07D403/12 , C07D403/14
Abstract: The specification describes the fumaric acid salt (A) of 2-(3-(4-(2-tert.butyl-6-trifluoromethyl- pyrimidin-4-yl)piperazin-1yl)propylmercapto)pyrimidin-4-ol (I). The fumaric salt of this known compound (WO96/02519) is reported to have very good affinity and high selectivity for the D3 receptor and is therefore useful for treating disorders which respond to dopamine D3 ligands such as schizophrenia, depressions, neuroses and psychoses.
-
公开(公告)号:AU1271201A
公开(公告)日:2001-04-30
申请号:AU1271201
申请日:2000-09-15
Applicant: BASF AG
Inventor: LUBISCH WILFRIED , KOCK MICHAEL , HOGER THOMAS , GRANDEL ROLAND , MULLER REINHOLD , SCHULT SABINE
IPC: A61K31/55 , A61P3/10 , A61P9/10 , A61P11/00 , A61P13/12 , A61P19/02 , A61P25/00 , A61P25/08 , A61P25/10 , A61P25/14 , A61P25/16 , A61P25/28 , A61P29/00 , A61P35/00 , C07D487/06 , C07D223/00 , C07D209/00
Abstract: The invention relates to compounds of formula (I) as well as to the tautomeric forms thereof, possible enantiomeric and diastereomeric forms and the prodrugs thereof, the production and use thereof, whereby the values have the meaning as given in the description.
-
公开(公告)号:AU4558400A
公开(公告)日:2000-11-21
申请号:AU4558400
申请日:2000-04-27
Applicant: BASF AG
Inventor: LUBISCH WILFRIED , KOCK MICHAEL , HOGER THOMAS , GRANDEL ROLAND , HOLZENKAMP UTA , SCHULT SABINE , MULLER REINHOLD
IPC: C07D235/20 , A61K31/415 , A61K31/4184 , A61K31/422 , A61K31/427 , A61K31/437 , A61K31/4439 , A61K31/4709 , A61K31/496 , A61K31/497 , A61P3/10 , A61P9/00 , A61P13/12 , A61P19/02 , A61P25/00 , A61P25/08 , A61P25/10 , A61P25/16 , A61P25/28 , A61P29/00 , A61P31/04 , A61P35/00 , A61P43/00 , C07D235/18 , C07D401/04 , C07D401/14 , C07D403/04 , C07D405/04 , C07D409/04 , C07D413/04 , C07D413/14 , C07D417/04 , C07D471/04
Abstract: The present invention relates to novel benzimidazoles, their preparation and their use as inhibitors of the enzyme poly(ADP-ribose) polymerase or PARP (EC 2.4.2.30) for producing drugs.
-
公开(公告)号:CA2371174A1
公开(公告)日:2000-11-02
申请号:CA2371174
申请日:2000-04-11
Applicant: BASF AG
Inventor: MULLER REINHOLD , KOCK MICHAEL , GRANDEL ROLAND , LUBISCH WILFRIED , SCHULT SABINE , HOGER THOMAS
IPC: C07D235/08 , A61K31/4184 , A61K31/4427 , A61K31/4523 , A61K31/496 , A61K31/551 , A61P3/10 , A61P9/00 , A61P9/10 , A61P13/12 , A61P19/02 , A61P25/00 , A61P25/08 , A61P25/16 , A61P25/28 , A61P29/00 , A61P31/04 , A61P35/00 , A61P35/04 , A61P43/00 , C07D235/10 , C07D235/12 , C07D235/14 , C07D235/16 , C07D401/08 , C07D403/08 , C07D235/06
Abstract: The invention relates to a compound of formula (I) or (II), wherein A represents a saturated or mono-unsaturated carbocycle containing 3 to 8 carb on atoms which can also have a condensed benzol ring, whereby the rings can als o be substituted with one or two different or identical radicals; R1 represent s hydrogen, chlorine, fluorine, bromine, iodine, branched and unbranched C1-C6 - alkyl, OH, nitro, CF3, CN, NR11R12, NH-CO-R13, O-C1-C4 alkyl; and R2 represents hydrogen, branched and unbranched C1-C6 alkyl, C1-C4 alkyl-phenyl . The invention also relates to the tautomeric forms, possible enantiomeric an d diastereomeric forms, possible cis-trans isomers on the rings in A and their prodrugs. The substituted benzimidazoles of general formulas (I) and (II) ar e inhibitors of poly(ADP-ribose) polymerase (PARP), or poly(ADP-ribose) syntha se (PARS), as it is also known and can be used for the treatment or prophylaxis of diseases which are associated with the increased enzyme activity of this enzyme.
-
公开(公告)号:ID24639A
公开(公告)日:2000-07-27
申请号:ID20000266
申请日:1998-08-14
Applicant: BASF AG
Inventor: BLANK STEFAN , SARCK DOROTHEA , TREIBER HANS-JORG , KOSER STEFAN , SCHAFER BERND , HOGER THOMAS
IPC: C07D239/56 , A61K20060101 , A61K31/395 , A61K31/497 , A61K31/505 , A61K31/506 , A61P1/08 , A61P25/16 , A61P25/18 , A61P25/20 , A61P25/24 , A61P43/00 , C07D20060101 , C07D239/42 , C07D239/46 , C07D295/125 , C07D403/00 , C07D403/12 , C07D403/14
Abstract: The fumaric acid salt (A) of 2-{3-[4-(2-tert. butyl-6-trifluoromethyl- pyrimidin-4-yl)piperazin-1- yl]propylmercapto}pyrimidin-4-ol (I) is new. The fumarate salt (A) of the pyrimidin-4-ol derivative of formula (I) is new. The tautomers, solvates and hydrates of (A) are also new. ACTIVITY : Neuroleptic; antidepressant; antiemetic; antihistamine. MECHANISM OF ACTION : Dopamine D 3 receptor ligand. (A) has a selectivity Ki D 2/Ki D 3 of 120.
-
公开(公告)号:AU1379800A
公开(公告)日:2000-06-05
申请号:AU1379800
申请日:1999-11-05
Applicant: BASF AG
Inventor: LUBISCH WILFRIED , KOCK MICHAEL , HOGER THOMAS
IPC: C07D235/18 , A61K20060101 , A61K31/10 , A61K31/404 , A61K31/41 , A61K31/4184 , A61K31/454 , A61P20060101 , A61P3/10 , A61P7/02 , A61P9/00 , A61P13/12 , A61P25/00 , A61P25/08 , A61P25/14 , A61P25/16 , A61P25/28 , A61P29/00 , A61P31/00 , A61P35/00 , A61P35/04 , A61P37/02 , A61P43/00 , C07D20060101 , C07D209/14 , C07D235/04
Abstract: 2-Phenylbenzimidazoles and 2-phenylindoles of formula IwhereinA is N or CH,R1 is hydrogen or alkyl which optionally carries an OR11 group,R11 is hydrogen or alkyl,R2 is hydrogen, chlorine, fluorine, bromine, iodine, alkyl, nitro, CF3, CN, NR21R22, NH-CO-R23, OR21,R21 and R22 are each hydrogen or alkyl,R23 is hydrogen, alkyl or phenyl,R3 is -(CH2)q-NR31R32,q is 0, 1, 2 or 3,R31 is hydrogen, alkyl, (CH2)rNR33R34,R32 is (CH2)rNR33R34,r is 2, 3, 4, 5 or 6,R33 and R34 are each hydrogen, alkyl or phenylalkyl wherein the phenyl ring is optionally substituted, orR33 and R34 and the nitrogen atom form a 3- to 8-membered ring,R4 is hydrogen, alkyl, chlorine, bromine, fluorine, nitro, cyano, NR41R42, NH-CO-R43, OR41,R41 and R42 are each hydrogen or alkyl, andR43 is alkyl or phenyl,are useful as inhibitors of poly(ADP-ribose)polymerase and for the production of drugs.
-
公开(公告)号:CA2350734A1
公开(公告)日:2000-05-25
申请号:CA2350734
申请日:1999-11-05
Applicant: BASF AG
Inventor: KOCK MICHAEL , HOGER THOMAS , LUBISCH WILFRIED
IPC: C07D235/18 , A61K20060101 , A61K31/10 , A61K31/404 , A61K31/41 , A61K31/4184 , A61K31/454 , A61P20060101 , A61P3/10 , A61P7/02 , A61P9/00 , A61P13/12 , A61P25/00 , A61P25/08 , A61P25/14 , A61P25/16 , A61P25/28 , A61P29/00 , A61P31/00 , A61P35/00 , A61P35/04 , A61P37/02 , A61P43/00 , C07D20060101 , C07D209/14 , C07D235/04
Abstract: The invention relates to the use of 2-phenyl-benzimidazoles and 2- phenylindoles of general formula (I), wherein A means N or CH, R1 means hydrogen, branched and unbranched C1-C6 alkyl and a C-atom of the alkyl radical can also carry an OR11 or a group R5, R2 means hydrogen, chlorine, fluorine, bromine, iodine, branched and unbranched C1-C6 alkyl, nitro, CF3, CN, NR21R22, NH-CO-R23, OR21, R3 means(CH2)q-NR31R32 and q can be 0, 1, 2 or 3 and R4 means hydrogen, branched and unbranched C1-C6 alkyl, chlorine, bromin e, fluorine, nitro, cyano, NR41R42, NH-CO-R43, OR41; as inhibitors of the enzym e poly(ADP-ribose)-polymerase for producing medicaments.
-
公开(公告)号:AU1266500A
公开(公告)日:2000-05-22
申请号:AU1266500
申请日:1999-10-28
Applicant: BASF AG
Inventor: LUBISCH WILFRIED , KOCK MICHAEL , HOGER THOMAS
IPC: G01N33/53 , A61K31/00 , A61K31/4184 , A61K31/4427 , A61K31/454 , A61K31/496 , A61K31/55 , A61P3/10 , A61P9/00 , A61P9/10 , A61P11/00 , A61P13/12 , A61P25/08 , A61P25/10 , A61P25/28 , A61P29/00 , A61P35/00 , A61P37/00 , A61P43/00 , C07C237/30 , C07D235/18 , C07D401/10 , C07D403/10 , C07D521/00 , C12Q1/48 , G01N33/00 , G01N33/15 , G01N33/573 , G01N33/577
Abstract: 2-Phenyl-benzimidazolecarboxamide derivatives (I) and (II) are new. 2-Phenyl-benzimidazolecarboxamide derivatives of formulae (I) and (II) and their tautomers, enantiomers, diastereomers, prodrugs and salts, are new: [Image] R 1>H or alkyl optionally substituted with OH, alkoxy, amino (optionally mono- or disubstituted) or optionally substituted piperidino, piperazino, pyrrolidino, hexahydroazepino, morpholino or 4,5-dihydropyridino; R 2>H, Cl, Br, I, F, CF 3, NO 2, NHCOR 2> 1>, NR 2> 2>R 2> 3>, OH, alkoxy, alkoxy-Ph, NH 2, or Ph; R 2> 1>, R 2> 2>alkyl; R 2> 3>H, alkyl, or optionally substituted phenyl; x : 0-2; R 3>D-(F 1>) p-(E) q-(F 2>) r-G, E-(D) u-(F 2>) s-(G) v or B; R 4>H, Cl, F, Br, I, alkyl, OH, NO 2, CF 3, CN, NR 4> 4>R 4> 2>, NHCOR 4> 3>, or alkoxy; R 4> 1>, R 4> 2>H or alkyl; R 4> 3>H, alkyl, alkyl-phenyl, or phenyl; D : O or S; E : phenyl, imidazole, pyrrole, thiophene, pyridine, pyrimidine, piperazine, pyrazine, furan, thiazole, isoxazole, pyrrolidine, piperidine or optionally substituted trihydroazepine ring; F 1>, F 2>1-8C chain optionally substituted with OH or alkoxy; p-v : 0 or 1, but p, q and r are not simultaneously 0; G : NR 5> 1>R 52>or optionally substituted pyrrolidinyl, piperidinyl, 1,2,5,6-tetrahydropyridyl, piperizinyl, azepinyl, morpholinyl or 1,4-diazepanyl; R 5> 1>alkyl or (CH 2) t-K; B : optionally substituted pyrrolidinyl, piperidinyl, 1,2,5,6-tetrahydropyridyl, piperizinyl, azepinyl, morpholinyl or 1,4-diazepanyl; t : 0-4; K : optionally substituted phenyl, NR 4> 1>R 4> 2>, phenyl-alkyl-NH, pyrrolidino, piperidino, 1,2,5,6-tetrahydropyridino, morpholino, trihydroazepino, or piperazino or homopiperazino (both optionally substituted with alkyl); R 5>H, alkyl, NR 7>R 9>, or optionally substituted pyrrolidinyl, piperidinyl, 1,2,5,6-tetrahydropyridyl, piperizinyl, azepinyl, morpholinyl or 1,4-diazepanyl; The full definitions are given in the DEFINITIONS (Full Definitions) Field. Independent claims are also included for the following: (i) aminobenzamide intermediates of formulae (III) and (IV) and their salts; (ii) preparation of compounds (III) and (IV); (iii) an in vitro method for the detection of poly(ADP-ribose)polymerase (PARP) inhibitors comprising: (a) incubating a poly-ADP-ribosylable target (optionally bonded to a carrier) with a reaction mixture comprising a PARP, a PARP activator and a PARP inhibitor or an analyte in which one or more PARP inhibitors is presumed to exist; (b) carrying out a poly-ADP-ribosylation reaction; and (c) qualitatively or quantitatively determining the poly-ADP-ribosylation with an anti-poly-(ADP-ribose) antibody. [Image] ACTIVITY : None given. MECHANISM OF ACTION : Poly(ADP-ribose)polymerase (PARP) inhibitor.
-
-
-
-
-
-
-
-
-